The week in 60 seconds
What happened, and nothing elseRecords on an oil headline, while the average stock sat the week out
- The S&P 500 rose 3.7% and set a record close of 7,736.52 on Tuesday, but the equal weight version of the same index rose only 1.5%, so the average stock captured well under half the gain.
- Oil did the lifting and then took some of it back. West Texas Intermediate fell 6.6% for the week after the Treasury Secretary said a Strait of Hormuz deal could come within days, then rose 3.8% on Thursday when Iran published a restrictive draft plan.
- The week's biggest winners were not the giants. CACI rose 31.7% and Zebra Technologies 26.2%, both after raising full year guidance, while Microsoft and Nvidia gained about 11% and 12%.
You have the headline. The brief adds the market setup behind it, a line on each of the five, and what matters next. Continue to the 5-minute brief →
The 5-minute brief
~3 minMarket read
Measured from the July 30 close through Thursday, August 6, the S&P 500 rose 3.7% to 7,709.96, the Nasdaq Composite gained 4.9% and the Dow added 3.2%. Both the S&P 500 and the Dow set record closes along the way, 7,736.52 on Tuesday and 54,349.12 on Wednesday. The trigger was oil. After Treasury Secretary Scott Bessent said on August 4 that the United States and Iran could reach a deal to reopen the Strait of Hormuz within days, West Texas Intermediate crude fell from $83.59 to $75.22 in three sessions and volatility dropped to 15.15. But the equal weight version of the S&P 500, which counts the smallest company the same as the largest, rose only 1.5%. A handful of very large companies did most of the work. The rally also stalled precisely when the oil story did: stocks slipped Wednesday and Thursday as Iran published a restrictive draft plan for the strait, said its shipping arrangement with Oman does not by itself reopen it, and crude climbed back to $78.09.
Market Risk Score: 47 / 100 (Moderate).
The risk score grades overall market conditions from 0 (calm) to 100 (high risk). It sets how cautious the week's read is. It is not a signal to buy or sell anything.
The five
- 01CACI, view score cardCACI Internationalguidance gapWeekly moveup 31.7 percent
Of everything that moved this week, this was the widest gap between what a company told investors to expect and what they had been expecting.
- 02ZBRA, view score cardZebra Technologiesrecord quarterWeekly moveup 26.2 percent
It raised guidance while absorbing a $120 million increase in memory costs, which is the harder version of a good quarter.
- 03CRL, view score cardCharles River Laboratoriesbookings turnWeekly moveup 13.2 percent
This is the one pick where the raise is about a business turning rather than a business accelerating.
- 04ELF, view score carde.l.f. Beautyoutlook raisedWeekly moveup 12.2 percent
It was one of the only consumer staples names to rise in a week when money left defensive sectors entirely, and the only one in my screen to raise a full year sales outlook by six percentage points.
- 05ARES, view score cardAres Managementrecord fundraisingWeekly moveup 11.3 percent
Fee related earnings are the part of an asset manager's profit that does not depend on markets rising, and they grew about 20% in the same quarter the firm raised more new money than it ever has.
Weekly move is each stock's movement during the window this issue analyzes (Week of July 30 to August 6, 2026), which closes before the issue publishes. It is not a return earned after publication. How each figure is measured →
You have the briefing.
Full research adds:
- the evidence behind the market read, and what would break it
- the complete case and the bear case on all five
- the next dated event for each name, and what result confirms or ends the thesis
- the primary sources every claim rests on
- the calls this issue is willing to be graded on next week
Full research
~10 minThis week's five
CACI, view score card · CACI International · Industrials / Government Technology
- Move before publication
- +31.7%
Rose about 31.7% for the week, with 21.4% of that in Thursday's session alone. Fourth quarter revenue rose 17.6% to $2.71 billion and adjusted earnings came in at $8.91 a share against roughly $7.32 expected. But the guidance was the news: fiscal 2027 revenue of $10.65 to $10.85 billion against about $9.55 billion expected, and adjusted earnings of $32.96 to $33.86 against about $28.16. A company does not guide a year that far above the consensus unless the work behind it is already contracted.
The catalyst. Fiscal 2026 fourth quarter results and initial fiscal 2027 guidance, released August 5: quarterly revenue of $2.71 billion, up 17.6%, adjusted earnings of $8.91 a share against about $7.32 expected, and fiscal 2027 guidance of $10.65 to $10.85 billion in revenue with at least $900 million of free cash flow. CACI International, August 5, 2026
Why it made the five. Of everything that moved this week, this was the widest gap between what a company told investors to expect and what they had been expecting. Guiding next year's revenue more than a billion dollars above the consensus is less a forecast about demand than a disclosure about contracts already won.
The case against it. The stock recovered roughly six months of going nowhere in a single session, so the news is now the price, and it closed above its prior sixty day high. Government technology revenue depends on federal budget timing, award schedules and contract protests, any of which can push revenue into a later year without anything actually going wrong. Guidance is also a promise about a fiscal year that has not started.
Weekly move (before publication): +31.7%
Every CACI appearance →Track this pick on the Scoreboard →Size a position in it →
ZBRA, view score card · Zebra Technologies · Technology / Enterprise Hardware
- Move before publication
- +26.2%
Gained about 26.2% for the week, essentially all of it in Tuesday's 26.5% session. Second quarter sales rose 20.4% to $1.557 billion, adjusted earnings jumped 76% to $6.35 a share, and management raised full year adjusted earnings guidance to $20.75 to $21.25 from $18.30 to $18.70. Read the growth carefully, though: roughly 8 percentage points of the full year outlook come from acquisitions, disposals and currency rather than from selling more.
The catalyst. Second quarter 2026 results, released August 4: net sales of $1,557 million, up 20.4%, non-GAAP earnings of $6.35 a share, adjusted EBITDA margin of 27.7%, and a raised full year outlook of 14% to 16% sales growth with non-GAAP earnings of $20.75 to $21.25 a share. Zebra Technologies, August 4, 2026
Why it made the five. It raised guidance while absorbing a $120 million increase in memory costs, which is the harder version of a good quarter. Management offset that with pricing rather than with cuts, and margins expanded anyway, by 710 basis points at the adjusted EBITDA line.
The case against it. About 8 points of the full year growth outlook come from acquisitions, disposals and currency, so the underlying business is growing far slower than the 20.4% headline suggests. The stock rose more than a quarter of its value in one session and sits near the top of its six month range, and the memory costs it just absorbed are an industry wide problem that does not end this quarter.
Weekly move (before publication): +26.2%
Every ZBRA appearance →Track this pick on the Scoreboard →Size a position in it →
CRL, view score card · Charles River Laboratories · Health Care / Drug Development Services
- Move before publication
- +13.2%
Rose about 13.2% for the week, with 11.4% of it on Wednesday. The quarter itself was unremarkable: revenue of $1.00 billion was down 2.7% from a year earlier and the company posted a GAAP loss of three cents a share. What moved the stock was the outlook. Management raised full year organic revenue growth guidance to a range of 0% to 1%, up from negative 1.5% to negative 0.5%, and said its drug development segment booked its highest net book to bill in nearly four years.
The catalyst. Second quarter 2026 results, released August 5: revenue of $1.00 billion, down 2.7%, organic growth of 0.1%, a GAAP loss of $(0.03) a share and non-GAAP earnings of $3.02 against about $2.74 expected, with full year organic revenue guidance raised to 0.0% to 1.0% and non-GAAP earnings raised to $11.15 to $11.45 a share. BioSpace, August 5, 2026
Why it made the five. This is the one pick where the raise is about a business turning rather than a business accelerating. Two years of shrinking research budgets at drug developers is what put this stock in a hole, and the highest bookings in nearly four years is the first real evidence that the shrinking has stopped.
The case against it. Revenue is still falling year over year and the company reported a GAAP loss, so this is an inflection argued from orders rather than from results. Book to bill measures work booked, not work delivered or paid for, and pharmaceutical research budgets can be cut again faster than a backlog converts into revenue.
Weekly move (before publication): +13.2%
Every CRL appearance →Track this pick on the Scoreboard →Size a position in it →
ELF, view score card · e.l.f. Beauty · Consumer Staples / Beauty
- Move before publication
- +12.2%
Rose about 12.2% in a week when the consumer staples sector fell 0.4%, making it one of very few defensive names to gain at all. First quarter sales rose 36% to $479.4 million and management raised its full year outlook to 18% to 20% sales growth from 12% to 14%. Two details deserve attention: roughly $160 million of the quarter came from Rhode, the skincare brand it acquired, and profit was flattered by about $50 million of tariff refunds that will not repeat.
The catalyst. Fiscal 2027 first quarter results, released August 5: net sales of $479.4 million, up 36%, with the acquired Rhode brand contributing about $160 million and roughly $50 million of tariff refunds in the quarter, and full year net sales growth guidance raised to 18% to 20% from 12% to 14%. StockTitan, August 5, 2026
Why it made the five. It was one of the only consumer staples names to rise in a week when money left defensive sectors entirely, and the only one in my screen to raise a full year sales outlook by six percentage points.
The case against it. Strip out Rhode and the tariff refund and the original e.l.f. brand is the soft part of this business, which makes the raise a statement about an acquisition more than about the core. The shares also rose 6.3% on August 4, two days before the results were public, so part of the week's gain was positioning rather than news.
Weekly move (before publication): +12.2%
Every ELF appearance →Track this pick on the Scoreboard →Size a position in it →
ARES, view score card · Ares Management · Financials / Asset Management
- Move before publication
- +11.3%
Rose about 11.3% for the week, with 8.2% of it on Monday, then gave part of the move back over the final two sessions. The firm raised a record $36.4 billion of new capital in the quarter, pushing assets under management up 17% from a year earlier to $671.3 billion, and lifted its dividend more than 20% to $1.35 a share. Adjusted earnings of $1.29 a share were actually about a penny short of expectations, which is the part the first day reaction skipped.
The catalyst. Second quarter 2026 results, released August 3: record gross capital raised of $36.4 billion, assets under management up 17% to $671.3 billion, fee related earnings of $491.1 million, up about 20%, after tax realized income of $1.29 a share against about $1.30 expected, and a quarterly dividend raised more than 20% to $1.35 a share. StockTitan, August 3, 2026
Why it made the five. Fee related earnings are the part of an asset manager's profit that does not depend on markets rising, and they grew about 20% in the same quarter the firm raised more new money than it ever has. That is the durable half of the business getting larger.
The case against it. Earnings actually came in a penny light, and the stock has already surrendered part of the pop and finished the week below its prior sixty day high. Most of that record fundraising went into private credit, the corner of the market drawing the most scrutiny over how loans are valued when they almost never trade.
Weekly move (before publication): +11.3%
Every ARES appearance →Track this pick on the Scoreboard →Size a position in it →
Stock of the week
CACI International (CACI, view score card)
Stock of the Week is the most instructive name in the issue, not the largest weekly mover.
Every pick in this issue raised its outlook, but CACI raised it by the widest margin, and the reaction shows what that is worth. The quarter itself was good and unremarkable: revenue up 17.6%, adjusted earnings ahead of expectations, and GAAP earnings actually down slightly from a year earlier. Then the company guided fiscal 2027 revenue to $10.65 to $10.85 billion against roughly $9.55 billion expected, and adjusted earnings to $32.96 to $33.86 against roughly $28.16, and the stock rose 21.4% in a single session. Government technology work is contracted years in advance, so a guidance number that far above the consensus reads less like optimism about demand and more like a disclosure about a backlog investors had underestimated. The honest caution is that this stock had gone essentially nowhere for six months and recovered all of it in one day, which means the good news is now the price. Guidance is also a promise about a fiscal year that has not begun, and federal award timing can move revenue between years without anyone doing anything wrong.
Sector rotation
Into: Technology · Consumer Discretionary · Communication Services · Industrials
Out of: Utilities · Energy · Real Estate · Consumer Staples
Rotation is money moving between industry groups. It shows where big investors added this week and where they pulled back.
Next week's watch
- The July consumer price index on Wednesday, August 12, the first inflation reading since the Federal Reserve held rates with three officials dissenting in favor of a hike
- Whether the Strait of Hormuz talks produce an actual agreement. Iran published a restrictive draft plan on Thursday and said its shipping route arrangement with Oman does not by itself reopen the strait, and crude rose 3.8% on the news
- Whether market breadth improves. The equal weight S&P 500 gained only 1.5% against 3.7% for the headline index, and a rally that narrow depends on a few very large companies continuing to work
- Coherent reports fiscal fourth quarter results on August 12. It rose 34.2% this week without reporting anything, on demand read across from other optical suppliers, and its results will test whether that was justified
- Whether the companies that raised guidance this week hold their gains. Several of them, including CACI and Zebra Technologies, repriced more than 20% in one session and now carry a much higher bar
Terms in this issue
Guidance Raise. When a company lifts its own forecast for the current year above the range it gave earlier. It is a statement about the future, separate from the results it just reported for the quarter that ended. More in the Learn hub →
Equal Weight Index. A version of an index that counts every company the same, rather than giving the largest companies the most influence. Comparing it to the standard index tells you whether a move came from the whole market or from a handful of giants.
Book to Bill. The ratio of new orders taken to work actually billed in the same period. Above one means a company is booking work faster than it is delivering it, which is usually a preview of future revenue rather than a description of current revenue.
Fee Related Earnings. The profit an asset manager earns from management fees charged on the money it oversees, separate from any share of investment gains. It is the steadier part of the business because it does not require markets to rise.
Organic Growth. Sales growth from the business a company already owned, stripping out acquisitions and currency effects. It answers whether a company is genuinely selling more, or whether the reported growth arrived by purchase.
Consensus Estimate. The average forecast of the analysts who follow a company. Share prices tend to reflect it already, which is why a company can report strong results and still fall, or report ordinary results and rise sharply after changing the forecast itself.